newsfilter
← Latest News
Business Wire·

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

-- Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist -- -- STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC